Showing 5911-5920 of 7127 results for "".
- Two New Psoriasis Guidelines Address Comorbidities, Biologic Treatmenthttps://practicaldermatology.com/news/two-new-psoriasis-guidelines-address-comorbidities-biologic-treatment/2459901/The American Academy of Dermatology and the National Psoriasis Foundation have released two new guidelines outlining best practices for treating psoriasis with a focus on comorbidities and biologic treatment. Develo
- Lutronic Genius RF Microneedling Platform Cleared by FDAhttps://practicaldermatology.com/news/lutronic-genius-rf-microneedling-platform-cleared-by-fda/2459905/Lutronic has received FDA clearance of the Lutronic Genius™ platform for radiofrequency microneedling. The company says the device transmits energy more precisely into the skin. The Lutronic Intelligent Care
- FDA Grants 510(k) Clearance to Laseroptek's PicoLOhttps://practicaldermatology.com/news/fda-grants-510k-clearance-to-laseropteks-picolo/2459903/Laseroptek’s PicoLO picosecond Nd:YAG laser is now U.S. Food and Drug Administration-cleared for marketing in dermatology and general and plastic surgery. According to the company, PicoLO generates high peak power and consistent picosecond pul
- International Awards for Social Responsibility in Dermatology Calls for Submissionshttps://practicaldermatology.com/news/international-awards-for-social-responsibility-in-dermatology-calls-for-submissions/2459907/Applications are being accepted online for the 2019 International Awards for Social Responsibility in Dermatology. This third edition of the Awards will recognize social initiatives led by dermatologists having
- MedPharm Ltd. Expands Partnership with Palvella Therapeutics, Inc. for PC Treatmenthttps://practicaldermatology.com/news/medpharm-ltd-expands-partnership-with-palvella-therapeutics-inc-for-pc-treatment/2459906/MedPharm Ltd, is expanding its partnership with Palvella Therapeutics, Inc. MedPharm has employed its formulation expertise to support Palvella’s development of a novel,
- New from BD: Prefillable Glass Syringe for Viscous Solutionshttps://practicaldermatology.com/news/new-from-bd-prefillable-glass-syringe-for-viscous-solutions/2459910/BD (Becton, Dickinson and Company) has presented BD Hylok,its new glass pre-fillable syringe for the administration of viscous solutions such as hyaluronic acid dermal fillers, at Pharmapack 2019. BD Hylokis also the first glass pre-fillab
- Key West Bans Sunscreens with Oxybenzone and Octinoxatehttps://practicaldermatology.com/news/key-west-bans-sunscreens-with-oxybenzone-and-octinoxate/2459911/Following Hawaii’s lead, Florida’s Key West City Commission voted to ban the sale of products that contain oxybenzone or octinoxate — two chemicals in sunscreen that have been shown to wash off and potentially damage coral reefs. The ban takes effect in January 2021. Fir
- Biologics May Reduce Plaque Buildup in Psoriasis Patients' Arterieshttps://practicaldermatology.com/news/biologics-may-reduce-plaque-buildup-in-psoriasis-patients-arteries/2459913/Treating psoriasis with biologic drugs can reduce the early plaque buildup that clogs arteries, restricts blood flow, and leads to heart attacks and stroke, according to a study funded by the Natio
- Jeuveau from Evolus Now FDA Cleared for Aesthetic Injectionhttps://practicaldermatology.com/news/jeuveau-from-evolus-now-fda-cleared-for-aesthetic-injection/2459914/The FDA has approved Jeuveau™ (prabotulinumtoxinA-xvfs), the lead product from Evolus, Inc., for the temporary improvement in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activity in adults. It will be available to physicians this sp
- Menlo Therapeutics to Present Late-Breaking Oral Presentation at AAD Annual Meetinghttps://practicaldermatology.com/news/menlo-therapeutics-to-present-late-breaking-oral-presentation-at-aad-annual-meeting/2459917/Menlo Therapeutics Inc., a late-stage biopharmaceutical company focused on the development of serlopitant for the treatment of pruritus, has had its abstract accepted for oral presentation at the Late-Breaking Research Program during the 2019 Annual Meeting in Washington, DC. The ab